Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Neurology

Advanced Treatments for Drug-Resistant Epilepsy

At a Glance

When familial temporal lobe epilepsy remains uncontrolled after two suitable seizure medicines, a specialized epilepsy center can map where seizures begin and assess surgery, laser treatment, or brain-stimulation devices. The best option depends on seizure location, memory, language, and goals.

For many people with familial temporal lobe epilepsy (FTLE), medications provide excellent control. However, for some, seizures continue despite trying several different drugs. When this happens, the condition is called drug-resistant epilepsy (DRE), and it may be time to explore advanced treatment options at a specialized center [1].

Defining Drug-Resistant Epilepsy

You are considered to have drug-resistant epilepsy if you have tried two different antiseizure medications (ASMs) that were chosen correctly for your seizure type and taken at adequate doses, but you still have seizures [1][2].

If you reach this point, medical guidelines recommend a referral to an Epilepsy Center (such as a Level 3 or Level 4 center, depending on the health system) [3]. These centers are staffed by a multidisciplinary team who work together to determine if your seizures are coming from one specific “focal” spot that can be treated directly [4][5].

Creating a “Brain Map”

Before any advanced treatment, doctors must create a precise map of where your seizures start and how those areas relate to your memory, speech, and movement [6]. This presurgical evaluation may include:

  • Advanced Imaging (PET and SPECT): An FDG-PET scan commonly demonstrates areas of decreased glucose metabolism between seizures, rather than a direct “hot spot.” A SPECT scan tracks blood flow but depends heavily on rapid injection during an actual seizure. Both provide complementary clues [7][8].
  • MEG (Magnetoencephalography): This test maps interictal (between-seizure) magnetic discharges, providing complementary mapping data [9].
  • SEEG (Stereoelectroencephalography): Doctors may place thin electrodes deep into the brain to record seizures directly from the source [10]. While SEEG can greatly improve localization, it carries procedural risks and does not always identify a single treatable source [11].
  • Neuropsychological Testing: Intensive “brain puzzles” measure your baseline memory and language skills. This helps predict how a procedure might affect your daily life [12][13].

Surgical and Ablative Options

If your seizures consistently start in one area that isn’t essential for critical functions, your team may suggest a procedure to remove or neutralize that spot.

  1. Anterior Temporal Lobectomy (ATL): This involves removing the front part of the temporal lobe. In highly selected populations (such as those with unilateral mesial temporal epilepsy and sclerosis), long-term seizure freedom rates can be between 60% and 80% [14][15]. However, these statistics do not apply to all forms of FTLE.
  2. Selective Amygdalohippocampectomy (SAH): A targeted procedure that removes only the deep structures (the amygdala and hippocampus) [16]. Seizure control rates are generally similar to ATL [17].
  3. Laser Interstitial Thermal Therapy (LITT): A minimally invasive option where a surgeon uses a laser probe to destroy the seizure focus. Seizure-free rates in selected patients (around 50% to 60%) may be slightly lower than open resection [18][15].

Note on Surgical Risks: All resective and ablative procedures carry risks, including the possibility of recurrent seizures, meaningful changes to memory or language, visual-field deficits, hemorrhage, and infection. A detailed discussion with your center is essential.

Neuromodulation: When Surgery Isn’t an Option

Sometimes, seizures start in multiple places (bilateral) or in an area of the brain that is too important to remove. In these cases, neuromodulation—using a device to “quiet” the brain’s electrical activity—is an option [19]. These devices generally aim to reduce the number of seizures rather than eliminate them entirely, and medication usually must continue [20].

  • RNS (Responsive Neurostimulation): A device implanted in the skull that constantly monitors your brain waves and delivers a tiny pulse of electricity when it detects a seizure starting [19].
  • VNS (Vagus Nerve Stimulation): A device placed in the chest that sends regular pulses of electricity via the vagus nerve in the neck to help prevent seizures over time [21].
  • DBS (Deep Brain Stimulation): Electrodes are placed into a deep part of the brain called the anterior nucleus of the thalamus. The device acts like a pacemaker, delivering stimulation to help stabilize electrical activity [20].

Common questions in this guide

When is familial temporal lobe epilepsy considered drug-resistant?
It is generally considered drug-resistant when a person continues to have seizures after trying two antiseizure medicines that were appropriate for the seizure type and taken at adequate doses. At that point, referral to a specialized epilepsy center is recommended for a detailed evaluation.
What tests can show where my seizures start?
A surgical evaluation may use PET and SPECT scans, MEG, and sometimes stereo-electroencephalography (SEEG), which records electrical activity with electrodes placed deep in the brain. Neuropsychological testing also measures memory and language so the team can compare seizure location with important brain functions.
Could surgery make me seizure-free?
Some carefully selected people with seizures starting in one removable area may become seizure-free after anterior temporal lobectomy or selective amygdalohippocampectomy, and laser treatment is another option. Results vary widely, and seizure-free rates reported for selected unilateral mesial temporal epilepsy groups do not apply to every person with familial temporal lobe epilepsy.
What is LITT, and how does it differ from open surgery?
Laser interstitial thermal therapy uses a thin laser probe to destroy the area where seizures begin through a minimally invasive procedure. In selected patients, seizure-free rates are often around 50% to 60% and may be somewhat lower than with open resection, but candidacy depends on the seizure map and nearby brain functions.
What treatments are available if epilepsy surgery is too risky?
Neuromodulation devices can reduce seizure frequency when seizures begin in multiple areas or in a part of the brain that should not be removed. Responsive neurostimulation (RNS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS) work in different ways; most people continue antiseizure medicines, and these treatments do not always stop seizures completely.
What risks should I discuss before epilepsy surgery?
Possible risks include seizures returning, changes in memory or language, loss of part of the visual field, bleeding, and infection. Brain mapping and memory-and-language testing help the team estimate how a procedure could affect daily function, but they cannot eliminate all risk.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do my current results meet the official definition of drug-resistant epilepsy?
  2. 2.If we move forward with a surgical evaluation, which specific tests—like PET, SPECT, or MEG—do I need to complete my 'brain map'?
  3. 3.Am I a candidate for a minimally invasive option like Laser Interstitial Thermal Therapy (LITT)?
  4. 4.Based on my language and memory testing, what are the specific risks to my daily function if we proceed with a resection?
  5. 5.If surgery is not an option, would a device like RNS or VNS be a better fit for my seizure pattern?
  6. 6.How many procedures of this type has this center performed in the last year, and what are your typical outcomes for patients like me?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Evaluation and management of drug resistant epilepsy in children.

    Kumar G

    Current problems in pediatric and adolescent health care 2021; (51(7)):101035 doi:10.1016/j.cppeds.2021.101035.

    PMID: 34305005
  2. 2

    Advances in Therapy for Refractory Epilepsy.

    Jehi L

    Annual review of medicine 2025; (76(1)):389-402 doi:10.1146/annurev-med-050522-034458.

    PMID: 39532109
  3. 3

    Drug resistance in epilepsy.

    Perucca E, Perucca P, White HS, Wirrell EC

    The Lancet. Neurology 2023; (22(8)):723-734 doi:10.1016/S1474-4422(23)00151-5.

    PMID: 37352888
  4. 4

    What can we do for people with drug-resistant epilepsy? The 2016 Wartenberg Lecture.

    Engel J

    Neurology 2016; (87(23)):2483-2489 doi:10.1212/WNL.0000000000003407.

    PMID: 27920283
  5. 5

    Getting the best outcomes from epilepsy surgery.

    Vakharia VN, Duncan JS, Witt JA, et al.

    Annals of neurology 2018; (83(4)):676-690 doi:10.1002/ana.25205.

    PMID: 29534299
  6. 6

    Diagnosis and Surgical Treatment of Drug-Resistant Epilepsy.

    Anyanwu C, Motamedi GK

    Brain sciences 2018; (8(4)) doi:10.3390/brainsci8040049.

    PMID: 29561756
  7. 7

    Resistant Temporal Lobe Epilepsy: Initial Steps into a Bigger Epilepsy Surgery Program.

    Mehrotra A, Singh S, Kanjilal S, et al.

    Journal of neurosciences in rural practice 2021; (12(1)):193-196 doi:10.1055/s-0040-1716796.

    PMID: 33531782
  8. 8

    Metabolic profiles and correlation with surgical outcomes in mesial versus neocortical temporal lobe epilepsy.

    Zhu HY, Tang YX, Xiao L, et al.

    CNS neuroscience & therapeutics 2023; (29(9)):2656-2665 doi:10.1111/cns.14209.

    PMID: 37017415
  9. 9

    Multimodal effective connectivity analysis reveals seizure focus and propagation in musicogenic epilepsy.

    Klamer S, Rona S, Elshahabi A, et al.

    NeuroImage 2015; (113()):70-7.

    PMID: 25797835
  10. 10

    Exploration of epileptic networks in temporal lobe encephaloceles with stereotactic EEG: Electroclinical characteristics and surgical outcomes.

    Zillgitt AJ, Mong ER, Manasseh AM, et al.

    Epilepsia open 2024; (9(6)):2395-2407 doi:10.1002/epi4.13063.

    PMID: 39374038
  11. 11

    The usefulness of stereo-electroencephalography (SEEG) in the surgical management of focal epilepsy associated with "hidden" temporal pole encephalocele: a case report and literature review.

    de Souza JPSAS, Mullin J, Wathen C, et al.

    Neurosurgical review 2018; (41(1)):347-354 doi:10.1007/s10143-017-0922-0.

    PMID: 29039074
  12. 12

    Long-term predictors of seizure outcome after anterior temporal lobectomy in unilateral hippocampal sclerosis: A 281-patient cohort with mean 10-year follow-up.

    Rodrigues TP, Bocca LF, Yacubian EMT, et al.

    Epileptic disorders : international epilepsy journal with videotape 2026; (28(1)):84-96 doi:10.1002/epd2.70139.

    PMID: 41277760
  13. 13

    Memory assessment in patients with temporal lobe epilepsy to predict memory impairment after surgery: A systematic review.

    Parra-Díaz P, García-Casares N

    Neurologia 2019; (34(9)):596-606 doi:10.1016/j.nrl.2017.02.012.

    PMID: 28433263
  14. 14

    Minimally invasive surgical approaches for temporal lobe epilepsy.

    Chang EF, Englot DJ, Vadera S

    Epilepsy & behavior : E&B 2015; (47()):24-33.

    PMID: 26017774
  15. 15

    Laser Interstitial Thermal Therapy versus Open Surgery for Mesial Temporal Lobe Epilepsy: A Systematic Review and Meta-Analysis.

    Ekman FR, Bjellvi J, Ljunggren S, et al.

    World neurosurgery 2024; (192()):224-235.e15 doi:10.1016/j.wneu.2024.09.090.

    PMID: 39332763
  16. 16

    An examination of seizure-free outcome and visual field deficits: Anterior temporal lobectomy versus selective amygdalohippocampectomy for temporal lobe epilepsy-a systematic review and meta-analysis for comprehensive understanding.

    Rangwala BS, Rangwala HS, Shafique MA, et al.

    Acta neurochirurgica 2024; (166(1)):487 doi:10.1007/s00701-024-06383-6.

    PMID: 39607527
  17. 17

    Verbal learning and memory outcome in selective amygdalohippocampectomy versus temporal lobe resection in patients with hippocampal sclerosis.

    Foged MT, Vinter K, Stauning L, et al.

    Epilepsy & behavior : E&B 2018; (79()):180-187 doi:10.1016/j.yebeh.2017.12.007.

    PMID: 29306849
  18. 18

    Long-term outcomes of mesial temporal laser interstitial thermal therapy for drug-resistant epilepsy and subsequent surgery for seizure recurrence: a multi-centre cohort study.

    Youngerman BE, Banu MA, Khan F, et al.

    Journal of neurology, neurosurgery, and psychiatry 2023; (94(11)):879-886 doi:10.1136/jnnp-2022-330979.

    PMID: 37336643
  19. 19

    Brain-responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy.

    Geller EB, Skarpaas TL, Gross RE, et al.

    Epilepsia 2017; (58(6)):994-1004 doi:10.1111/epi.13740.

    PMID: 28398014
  20. 20

    Neuromodulation for Refractory Epilepsy.

    Ryvlin P, Jehi LE

    Epilepsy currents 2022; (22(1)):11-17 doi:10.1177/15357597211065587.

    PMID: 35233189
  21. 21

    Practical considerations in epilepsy neurostimulation.

    Simpson HD, Schulze-Bonhage A, Cascino GD, et al.

    Epilepsia 2022; (63(10)):2445-2460 doi:10.1111/epi.17329.

    PMID: 35700144

This page is for informational purposes only and does not constitute medical advice. An epilepsy center team should assess whether surgery, laser treatment, or neuromodulation is appropriate for your seizure pattern and goals.

Get notified when new evidence is published on Familial temporal lobe epilepsy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.